{"id":62778,"date":"2026-03-12T10:06:37","date_gmt":"2026-03-12T09:06:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/"},"modified":"2026-03-12T10:06:37","modified_gmt":"2026-03-12T09:06:37","slug":"mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/","title":{"rendered":"MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale"},"content":{"rendered":"
\n

\nFormer Rune Labs and Glooko executive to lead MindMaze\u2019s next phase of growth, focusing on U.S. market expansion and the delivery of scalable, AI-driven neurorestorative care.<\/i><\/b><\/p>\n

GENEVA–(BUSINESS WIRE)–MindMaze Therapeutics Holding SA (SIX: MMTX<\/a>) (MindMaze Therapeutics, or the Company), a global leader in brain technology and precision neurotherapeutics, today announced the appointment of Zach Henderson as Chief Executive Officer. Mr. Henderson joins at a pivotal inflection point as the Company invests in scaling its existing commercial presence, focused on accelerating adoption of its FDA-cleared platform in the United States to address the widening supply-demand gap in neurological care.<\/p>\n

\nWith over 30 years of experience, Mr. Henderson has a proven track record of scaling healthcare technology platforms and driving significant recurring revenue growth. His most recent role as Chief Commercial Officer at Rune Labs and his prior tenure as CEO of PKG Health underscore his expertise in commercializing AI-driven solutions for complex chronic conditions like Parkinson\u2019s.<\/p>\n

\n“MindMaze has built the industry\u2019s most rigorous clinical foundation. Our mission now is to translate that scientific leadership into widespread market adoption,”<\/i> said Walid Hanna, Chairman of the Board. “Zach\u2019s operational depth and success across global markets make him the ideal leader to drive our commercial expansion and deliver value to our shareholders.”<\/i><\/p>\n

\nThe global healthcare system faces a critical shortage of neurologists and specialized therapists (PT\/OT), leaving millions of patients with stroke, Parkinson\u2019s disease, and Alzheimer\u2019s with insufficient access to recovery. MindMaze is redefining this paradigm by shifting care from episodic, clinic-bound sessions to continuous, data-driven neurorestoration accessible at scale in both clinical and home settings.<\/p>\n

\n“I am honored to lead MindMaze as we solve one of healthcare\u2019s most pressing capacity challenges,” <\/i>said Zach Henderson. “By digitizing the neuro-restorative journey, we are providing a scalable solution to a global shortage of specialized care providers. We are redefining the standard of care for tens of millions of patients worldwide.”<\/i><\/p>\n

\nMr. Alexandre Capet has been appointed Chief Operating and Strategy Officer continuing his service as a standing member of the Company\u2019s Executive Committee.<\/p>\n

\nAbout MindMaze Therapeutics<\/b><\/p>\n

\nMindMaze Therapeutics (SIX: MMTX<\/a>) is a global leader in brain technology, dedicated to redefining the recovery trajectory for patients with neurological platform-based digital treatments. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to the home-based therapy. The Company\u2019s FDA-cleared and CE-marked neurotherapeutics are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson\u2019s disease, and other brain disorders. With a commitment to rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.<\/p>\n

\nFor more information, visit www.mindmazetherapeutics.com<\/a>.<\/p>\n

\nDISCLAIMER<\/b><\/p>\n

\nThis press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company’s ability to execute its strategy. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia & Investor Contacts
\n
Investor Relations:<\/b>
Jeremy Meinen, Chief Financial Officer
\n
ir@mindmazetherapeutics.com<\/a><\/p>\n

\nMedia Inquiries:<\/b>
VSC for MindMaze Therapeutics
\n
mindmazetherapeutics@vsc.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Former Rune Labs and Glooko executive to lead MindMaze\u2019s next phase of growth, focusing on U.S. market expansion and the delivery of scalable, AI-driven neurorestorative care. GENEVA–(BUSINESS WIRE)–MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a global leader in brain technology and precision neurotherapeutics, today announced the appointment of Zach Henderson as … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62778","6":"format-standard","7":"category-industry"},"yoast_head":"\nMindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Former Rune Labs and Glooko executive to lead MindMaze\u2019s next phase of growth, focusing on U.S. market expansion and the delivery of scalable, AI-driven neurorestorative care. GENEVA–(BUSINESS WIRE)–MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a global leader in brain technology and precision neurotherapeutics, today announced the appointment of Zach Henderson as ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-12T09:06:37+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale\",\"datePublished\":\"2026-03-12T09:06:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\\\/\"},\"wordCount\":616,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\\\/\",\"name\":\"MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2026-03-12T09:06:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/","og_locale":"en_US","og_type":"article","og_title":"MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale - Pharma Trend","og_description":"Former Rune Labs and Glooko executive to lead MindMaze\u2019s next phase of growth, focusing on U.S. market expansion and the delivery of scalable, AI-driven neurorestorative care. GENEVA–(BUSINESS WIRE)–MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a global leader in brain technology and precision neurotherapeutics, today announced the appointment of Zach Henderson as ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-12T09:06:37+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale","datePublished":"2026-03-12T09:06:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/"},"wordCount":616,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/","url":"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/","name":"MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2026-03-12T09:06:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62778"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62778\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}